연구성과로 돌아가기

2020 연구성과별 연구자 정보 (65 / 2428)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Kang, Won Ki Kang, WK 9 Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Yeh, Kun-Huei Yeh, KH 10 Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan HGD-3316-2022 Yeh, Kun-Huei 0000-0002-7306-174X YEH, Kun-Huei nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Yeh, Kun-Huei Yeh, KH 10 Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Oncol, Coll Med, Taipei, Taiwan HGD-3316-2022 Yeh, Kun-Huei 0000-0002-7306-174X YEH, Kun-Huei nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Yoshikawa, Takaki Yoshikawa, T 11 Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Kanagawa, Japan Y-1580-2019 Yoshikawa, Takaki nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Yoshikawa, Takaki Yoshikawa, T 11 Natl Canc Ctr, Dept Gastr Surg, Tokyo, Japan Y-1580-2019 Yoshikawa, Takaki nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Oh, Sang Cheul Oh, SC 12 Korea Univ, Coll Med, Dept Internal Med, Div Hematol & Oncol, Seoul, South Korea nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Bai, Li-Yuan Bai, LY 13 China Med Univ, China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Tamura, Takao Tamura, T 14 Kindai Univ, Fac Med, Dept Med Oncol, Osakasayama, Japan nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Tamura, Takao Tamura, T 14 Kindai Univ, Dept Med Oncol, Nara Hosp, Ikoma, Japan nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Lee, Keun-Wook Lee, KW 15 Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Hematol & Oncol,Coll Med, Seongnam, South Korea nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Hamamoto, Yasuo Hamamoto, Y 16 Keio Univ, Keio Canc Ctr, Sch Med, Tokyo, Japan AAA-9941-2022 Hamamoto, Yasuo 0000-0002-5737-122X Hamamoto, Yasuo nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Kim, Jong Gwang Kim, JG 17 Kyungpook Natl Univ, Sch Med, Daegu, South Korea nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Chin, Keisho Chin, K 18 Japanese Fdn Canc Res, Dept Gastroenterol, Canc Inst Hosp, Tokyo, Japan nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Oh, Do-Youn Oh, DY 19 Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea nboku@ncc.go.jp;
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Minashi, Keiko Minashi, K 20 Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan nboku@ncc.go.jp;
페이지 이동: